Related references
Note: Only part of the references are listed.Potentiating Endogenous Antitumor Immunity to Prostate Cancer through Combination Immunotherapy with CTLA4 Blockade and GM-CSF
Lawrence Fong et al.
CANCER RESEARCH (2009)
Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer
Douglas G. McNeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase 1/2 dose-escalation study of a GM-CSF-Secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer
Celestial S. Higano et al.
CANCER (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer
Brian Schurko et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems
Joseph F. Grosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer
Eric J. Small et al.
CLINICAL CANCER RESEARCH (2007)
Preclinical and clinical studies of recombinant poxvirus Vaccines for carcinoma therapy
Philip M. Arlen et al.
CRITICAL REVIEWS IN IMMUNOLOGY (2007)
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients
Ashley M. Miller et al.
JOURNAL OF IMMUNOLOGY (2006)
Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy:: The GVAX™ vaccine for prostate cancer
Jonathan W. Simons et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2006)
Differential proteomic alterations between localised and metastatic prostate cancer
B. S. Taylor et al.
BRITISH JOURNAL OF CANCER (2006)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials
Laurence Collette et al.
EUROPEAN JOURNAL OF CANCER (2006)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preoperative plasma levels of transforming growth factor beta1 (TGF-β1) strongly predict progression in patients undergoing radical prostatectomy
SF Shariat et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells
EJ Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
